Business
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021
Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure\nSOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were presented at Heart Failure 2021, an International Congress of the European Society of Cardiology, including a prespecified subgroup analysis of the influence of atrial fibrillation or flutter (AFF) on the treatment effect of omecamtiv mecarbil in a Late Breaking Clinical Trial Session. Other analyses were presented in the Clinical Trial Updates Session related to which patients in GALACTIC-HF achieved an increased treatment effect with omecamtiv mecarbil. “These new analyses add to other data from GALACTIC-HF underscoring that patients with markers of more severe heart failure derived greater treatment benefit from omecamtiv mecarbil,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “Many patients with severe heart failure still remain at risk, despite available guideline-directed therapy. Omecamtiv mecarbil may offer a new treatment option for these more severe heart failure patients who are also in greatest need.” GALACTIC-HF: Patients Without Atrial Fibrillation or Flutter Have Increased Treatment Effect with Omecamtiv Mecarbil Scott Solomon, M.D., the Edward D. Frohlich Distinguished Chair, Professor of Medicine, Harvard Medical School and Director of Noninvasive Cardiology, Brigham and Women's Hospital, presented additional analyses from GALACTIC-HF assessing how baseline AFF in patients impacted the effectiveness of omecamtiv mecarbil in GALACTIC-HF. Of the 8,256 patients enrolled in GALACTIC-HF, 2,245 patients (27%) had AFF at baseline; these patients were older, more likely to be randomized as inpatients, had a higher New York Heart Association (NYHA) class and had higher NT-proBNP compared to patients without AFF. The effect of treatment with omecamtiv mecarbil on the primary composite endpoint of heart failure events (heart failure hospitalization and other urgent treatment for heart failure) or cardiovascular (CV) death was greater i...